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Abstract 
Background & Aims: Response Evaluation Criteria in Solid Tumors (RECIST) has 
been shown to be a poor surrogate for survival benefit with targeted therapy in 
advanced hepatocellular carcinoma (HCC). Methods: We investigated whether 
response evaluated using modified RECIST (mRECIST) predicted overall survival 
(OS) using data from two Phase II clinical trials. Analyses were conducted on pooled 
data from 188 patients with advanced HCC treated with nintedanib or sorafenib, of 
whom 180 were evaluable for response. Cox regression and Kaplan–Meier survival 
analyses were used to explore differences in OS between the responders and non-
responders according to RECIST 1.0 and mRECIST criteria. Multivariate Cox 
proportional hazards models, including factors known to influence survival, were used 
to compare survival according to RECIST and mRECIST response. Results: 
Discordance between RECIST and mRECIST evaluation was most common for 
assessment of partial response (12.2%) and stable disease (13.3%). OS was 
significantly longer in patients with response compared to patients without response – 
RECIST: hazard ratio (HR) 0.325 (95% confidence interval [CI] 0.130–0.815); 
p=0.0122; mRECIST: HR 0.544 (95% CI 0.335–0.881); p=0.0122. HRs from the 
multivariate models used to evaluate response by RECIST or by mRECIST as 
predictors of OS approached significance for RECIST (0.40 [95% CI 0.16‒1.01]; 
p=0.053) and for mRECIST (0.62 [95% CI 0.38‒1.01]; p=0.053). Conclusions: 
Response according to RECIST or mRECIST is associated with improved survival 
and should be considered as a valid endpoint for use in HCC clinical trials. 
Word count: 237 (250 max) 
Keywords: angiogenesis, hepatocellular carcinoma, overall survival 
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Key points 
 mRECIST has been proposed as a more appropriate method to assess 
response in HCC, although evidence supporting use for systemic therapy is 
limited and conflicting; to our knowledge prospective studies have not been 
published 
 Data from two randomized Phase II trials in patients with HCC in which 
mRECIST and RECIST were prospectively compared, demonstrated a higher 
objective response rate for mRECIST vs RECIST 1.0 (15.6 vs 4.4%) 
 Response according to both mRECIST and RECIST 1.0 were independent 
predictors of survival 
 Both mRECIST and RECIST 1.0 can be used as validated response 
assessments in trials of systemic therapy for HCC 
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Introduction 
Overall survival (OS) has long been deemed to be the most clinically relevant 
endpoint for assessing treatment efficacy in late-phase oncology trials. As the 
traditional ‘gold standard’, OS constitutes a clear and unambiguous endpoint and, as 
such, is recommended for use as the primary endpoint in Phase III studies evaluating 
primary treatments in hepatocellular carcinoma (HCC) (1). One of the challenges for 
drug development in HCC has been the identification of a reliable surrogate for 
survival that can be evaluated in Phase II trials and used to justify transition to Phase 
III clinical development. The value of response based on Response Evaluation 
Criteria in Solid Tumors (RECIST) (2) has been questioned after two Phase III trials 
of sorafenib demonstrated a survival benefit despite a very low rate of response (3, 
4). According to conventional RECIST criteria, the response rate to sorafenib was 2‒
3%, yet the drug improved OS, apparently by delaying progression. This observation 
led to the proposal that time to progression (TTP) should be used in Phase II trials 
(1); however, recent trials have demonstrated that TTP is also not a reliable predictor 
of OS (5). 
More recently, modified RECIST (mRECIST) has been proposed as a more 
appropriate method for assessing response in HCC (6). Although conventional 
RECIST evaluates unidimensional measurement of target lesions, mRECIST 
evaluates target lesion dimensions according to the diameter of viable tumour, as 
defined by contrast enhancement in the arterial phase. It has been suggested that 
mRECIST is more reflective of the mechanism of action of targeted agents such as 
sorafenib, which can induce tumour necrosis without changing the overall size of the 
tumour. Since the publication of the mRECIST guidelines, many studies have 
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provided validation of use of mRECIST in the assessment of locoregional therapies, 
such as transcatheter embolisation (TAE)/transarterial chemoembolisation (TACE) 
(7-12). A recent meta-analysis of seven reports including 1357 patients demonstrated 
a hazard ratio (HR) for survival of 0.39 (95% confidence interval [CI]: 0.26‒0.61; 
p<0.0001) for mRECIST responders versus non-responders (13). However, as 
TAE/TACE causes acute devascularisation and necrosis, mRECIST response rates 
are high and correlation of mRECIST with outcome is unsurprising.  
In contrast, evidence to support the use of mRECIST for systemic therapy is 
much more limited and confined to four relatively small retrospective studies, three of 
which were single centre and one of which was multicentre (14-17). Two studies 
showed that mRECIST correlated with survival (14, 15), and in another study patients 
classified as responders by mRECIST had significantly better OS than patients 
classified as non-responders (17). However, the fourth study failed to show a 
significant relationship between the two (16). These conflicting findings, combined 
with the small, retrospective nature of these studies, warrant further investigation of 
the value of mRECIST in determining prognosis in HCC. Furthermore, for mRECIST 
to be accepted as a valid endpoint in Phase II clinical trials investigating the use of 
targeted therapy for patients with HCC, it must be validated prospectively in larger 
multicentre trials conducted in well-characterised patient populations. Of note, 
currently only RECIST (and not mRECIST) is recognised by the European Medicines 
Agency and the Food and Drug Administration as validated criteria for use in patients 
with advanced HCC. 
In this analysis, we used data from two Phase II clinical trials in HCC, in which 
responses by RECIST and mRECIST were prospectively collected. Both studies 
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were done to evaluate the efficacy of nintedanib and sorafenib, and found that these 
agents had similar efficacy in this patient population in terms of time to progression 
and OS (18, 19). In order to provide more robust evidence to support the use of 
mRECIST as a surrogate for survival, we investigated whether response evaluated 
using mRECIST predicted OS in these studies. 
 
Patients and methods 
Study design and patients 
Two multicentre, open-label, Phase I/randomised Phase II studies were conducted to 
evaluate the efficacy and safety of nintedanib versus sorafenib as first-line treatment 
of predominantly Caucasian patients (study 1199.37; NCT01004003) or Asian 
patients (study 1199.39; NCT00987935) with advanced HCC. The dose-escalation 
Phase I part of both studies was designed to establish the maximum tolerated dose 
(MTD) in two different groups according to liver function; patients with mild hepatic 
impairment (alanine/aspartate aminotransferase [ALT/AST] ≤2 times upper limit of 
normal (ULN) and Child–Pugh score 5–6) and patients with moderate hepatic 
impairment (ALT or AST >2 to ≤5 times ULN or Child–Pugh score 7). In both trials, 
the MTD of nintedanib was determined to be 200 mg bid in both liver function groups 
investigated. Data from the Phase I part of these studies were not included in the 
analysis reported here as complete efficacy data were not collected. In Phase II, 
patients were randomised 2:1 to receive nintedanib 200 mg bid or sorafenib 400 mg 
bid continuously in 28-day cycles until intolerable adverse events or progressive 
disease (PD). Treatment beyond PD was allowed at the discretion of the investigator. 
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Patient randomisation was stratified by presence of extrahepatic spread (EHS) and/or 
macrovascular invasion (MVI) (MVI and/or EHS present vs both absent). 
To be eligible for inclusion in either study, adult (≥18 years) patients with mild 
hepatic impairment (Child–Pugh score 5–6, ALT/AST levels ≤2 times ULN) were 
required to have advanced HCC not amenable to curative/locoregional therapy, ≥1 
measurable lesion by RECIST 1.0, Eastern Cooperative Oncology Group 
performance score (ECOG PS) ≤2, >4 weeks since most recent local therapy and no 
prior systemic therapy for HCC; further details of the inclusion/exclusion criteria are 
reported elsewhere (18, 19). Both trials were approved by the following health 
authorities and independent ethics committees or institutional review boards at each 
country/centre based on local regulations: Medicines and Medical Devices Agency 
(Austria), Agence Nationale de Sécurité du Médicament et des Produits de Santé 
(France), Federal Institute for Drugs and Medical Devices (Germany), National 
Institute of Pharmacy (Hungary), Central Committee Research Involving Human 
Subjects (The Netherlands), Registration of Medicinal Products, Medical Devices and 
Biocidal Products (Poland), National Medicines Agency (Romania), Ministry of Food 
and Drug Safety (South Korea), Department of Health (Taiwan), Medicines and 
Healthcare Products Regulatory Agency (UK) and Food and Drug Administration 
(US). They were conducted in accordance with the guiding principles of the 
Declaration of Helsinki, the International Council for Harmonisation Harmonised 
Tripartite Guideline for Good Clinical Practice, and local legislation. All patients 
provided written informed consent. 
In both trials, the primary endpoint was TTP by central independent review 
using RECIST 1.0. The secondary endpoints were centrally reviewed objective 
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tumour response and progression-free survival (PFS) using RECIST 1.0, and OS – 
defined as the duration from date of randomisation to the date of death. Further 
endpoints included TTP, objective tumour response and PFS by central review using 
mRECIST. 
Radiological assessment  
Tumour assessment was performed at screening and every 4 weeks for the first 16 
weeks after the start of treatment and every 8 weeks thereafter. Computed 
tomography/magnetic resonance imaging of the chest, abdomen and pelvis was 
mandatory, whereas assessment of other body parts was performed as clinically 
indicated; scans were to be performed within 5 days prior to the scheduled visit. 
Assessment of tumour response was done by blinded central radiological review 
using both RECIST 1.0 (2) and mRECIST criteria for HCC (6). One to 10 target 
lesions (not exceeding five lesions per organ) were identified at screening. Objective 
response (OR) was defined as a best response of complete response (CR) or partial 
response (PR); this categorisation was done according to RECIST and according to 
mRECIST. Patients with unknown response due to missing data were not evaluable 
and were excluded from our analyses.  
 
Statistical analysis  
To increase the number of responses, both treatment arms were pooled for this 
analysis, as study results suggest that nintedanib and sorafenib treatment are 
comparable (18, 19). Survival data were analysed using the Kaplan–Meier method. 
Differences in OS between responders and non-responders were evaluated using the 
 11/29 
Cox proportional hazards model stratified by MVI, EHS, or both present versus both 
absent, and study, where a HR of less than one favours response. The Score Test 
with Breslow method for tied observation times was used to determine p-values.  
Multivariate Cox proportional hazards models were used to compare survival 
according to RECIST and mRECIST response. Analyses were conducted, including 
factors known to influence survival. Baseline characteristics that have consistently 
shown to be prognostic indicators for OS in patients with advanced HCC treated with 
sorafenib include ECOG PS, extent of tumour burden (defined as presence or 
absence of MVI, EHS, or both), and baseline levels of alpha-fetoprotein (AFP), 
albumin and total bilirubin (4). Two multivariate selection analyses, stratified by study, 
were conducted to identify which individual baseline variables predict survival at the 
0.2 level of significance using the Likelihood Ratio Chi-Square Statistic with Breslow 
method for tied observation times to determine p-values. The selection models 
included RECIST or mRECIST response as a time-dependent covariate and other 
baseline variables (ECOG PS [0 vs >0], MVI [absent vs present], EHS [absent vs 
present], baseline albumin [<36 g/L vs ≥36 g/L], baseline bilirubin [<17 μmol/L vs ≥17 
μmol/L] and age [continuous variable]) as time-independent covariates. Baseline AFP 
levels were not included due to the large amount of missing data in Study 1.  
 
Results 
Patient disposition and demographics 
A total of 188 patients were randomised to treatment with nintedanib (1199.37: n=62; 
1199.39: n=63) or sorafenib (n=31; n=32). At the time of data analysis, the majority of 
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patients had discontinued treatment with nintedanib (97.6%) or sorafenib (98.4%); 
three nintedanib patients and one sorafenib patient remained on treatment at this 
point. Full details of baseline demographics and disease characteristics by treatment 
group in each trial have been reported previously and were generally balanced 
between treatment groups, supporting our approach to pool treatment arms. Baseline 
demographics and disease characteristics for the pooled population are shown in 
Table 1. The majority of patients were male (84%) and the median age was 63 years. 
 
Response assessment 
Of the 188 patients treated in these trials, 180 patients (95.7%) were evaluable for 
RECIST and mRECIST response. Six patients in the nintedanib group and two 
patients in the sorafenib group had unknown response or were not evaluable – these 
patients were excluded from the analyses. Best overall response by RECIST and 
mRECIST is reported in Table 2, and concordance/discordance between RECIST 
and mRECIST response is shown in Table 3. Discordance between RECIST and 
mRECIST evaluation was most common for assessment of PR (n=22; 12.2%) and 
stable disease (SD) (n=24; 13.3%). Of note, among the 141 patients (nintedanib 
n=89; sorafenib n=52) who were classified as having SD by RECIST, 21 (14.9%; 
nintedanib n=11; sorafenib n=10) were reclassified as having PR by mRECIST. 
Overall, there was good concordance between RECIST and mRECIST when used to 
assess PD, and there were only two patients in whom there was discordance, giving 
rise to a PD rate of 17.2% by RECIST and 16.1% by mRECIST. Variation in best 
percentage changes from baseline in target lesions is shown in Fig. 1. Of note, five 
patients had a 100% reduction from baseline in the sum of target lesion dimensions 
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according to mRECIST criteria (Fig. 1B); these patients did not qualify as having a 
CR in the OR assessment due to non-target lesions and new lesion assessments. 
 
 
 
Survival analysis according to radiological response  
At the time of analysis, 140 patients (77.8%) had died and the median OS for the 
total population was 11.4 months (interquartile range [IQR] 6.6–20.5) (Fig. 2A). 
Kaplan–Meier survival curves by RECIST and mRECIST response are shown in Fig. 
2B and 2C, respectively. OS was significantly longer in patients with RECIST 
response (n=8) compared to patients without RECIST response (23.6 months [IQR 
12.7–n.c.] vs 11.2 months [IQR 6.5–19.8]; HR 0.325 [95% CI 0.130–0.815]; 
p=0.0122). Similar results were found in patients with and without mRECIST 
response, in which the median OS was 16.7 months (IQR 10.7–28.4) in those with 
mRECIST response versus 10.9 months (IQR 6.2–18.2) in those without mRECIST 
response; HR 0.544 (95% CI 0.335–0.881); p=0.0122. The 1-year survival rate was 
75.0% in patients with RECIST response and 64.3% in patients with mRECIST 
response, with 2-year survival rates of 37.5% and 31.3%, respectively. The median 
OS in patients with both a RECIST and mRECIST response (n=7) was 23.9 months 
(IQR 17.3–n.c.).  
Patients who experienced PD as best OR by RECIST had a median OS of 4.3 
months and patients who experienced PD as best OR by mRECIST had a median 
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OS of 4.3 months (see supplementary Fig. 1). Median OS in patients with RECIST 
and mRECIST SD was 12.4 months and 11.9 months, respectively (see 
supplementary Fig. 1). Survival by concordance (i.e. in patients who exhibited a 
response according to RECIST and mRECIST, or according to only one of RECIST 
or mRECIST) is shown in Supplementary Table 1.  
Analyses of RECIST and mRECIST as predictors of survival  
HRs for OS from the multivariate model including RECIST or mRECIST and baseline 
variables are shown in Fig. 3. In both models, the presence of MVI and EHS at 
baseline were associated with worse OS. Neither RECIST response nor mRECIST 
response was a statistically significant predictor of survival, although both 
approached significance.  
Analysis of survival models 
Survival models were evaluated for relative quality. Two criteria for model selection 
were evaluated: the Akaike information Criterion (AIC) and the Schwarz Bayesian 
Information Criterion (SBC). For the final model selecting MVI, EHS and time-
dependent RECIST response, the AIC was 1056.883 and the SBC was 1065.708. 
For the final model selecting MVI, EHS and time-dependent mRECIST response, the 
AIC was 1057.546 and the SBC was 1066.370. In summary, both the AIC and SBC 
were similar between the final survival models; this indicates that it cannot be 
concluded that either one of RECIST or mRECIST is a better predictor of survival. 
Discussion  
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Previous research has suggested that RECIST, the standard method of response 
assessment for solid tumours, does not always represent the most appropriate tool 
for evaluation of response in patients with HCC, as it does not account for changes in 
lesion density that occur with targeted treatments. This is supported by observations 
from studies conducted with sorafenib, in which it was observed that significant 
improvements in survival compared to placebo were not accompanied by the 
expected differences in RECIST response rates; reported response rates with 
sorafenib by RECIST were only 2–3% (3, 4).  
Here, we have analysed data from two randomised Phase II clinical trials in 
patients with HCC to determine whether response assessed using mRECIST can 
predict OS. Our findings show that both RECIST and mRECIST are of value in 
predicting long-term survival in patients with HCC treated with antiangiogenic agents, 
and that those patients with an OR by RECIST or mRECIST had significantly better 
survival compared to patients who only achieve SD or PD as best treatment 
response. The AIC and SBC were similar between the survival model that included 
RECIST as a variable and the survival model that included mRECIST as a variable; 
this indicates that it cannot be concluded that either RECIST or mRECIST response 
predicts survival better than the other. 
These observations are in agreement with previously reported retrospective 
studies in patients treated with sorafenib that have also shown RECIST 1.1 and 
mRECIST response to successfully predict survival advantages compared to those 
without (14, 15). In a third study, patients classified as responders by mRECIST had 
significantly better OS than patients classified as non-responders (17). A fourth study 
conducted in 156 patients with HCC treated with sorafenib failed to show OS benefits 
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for RECIST 1.1 and mRECIST, although classification of response by mRECIST was 
found to be more strongly associated with OS than RECIST 1.1 (16).  
Our analysis shows that mRECIST criteria identified more patients with a 
response to treatment than RECIST (15.6% vs 4.4%). This would be expected based 
on differences in the determination of response between RECIST and mRECIST, and 
higher response rates have also been consistently reported in retrospective 
evaluations (23% mRECIST vs 2% RECIST 1.1 (14); 28% mRECIST vs 3% RECIST 
1.1 (15); 23% mRECIST vs 10% RECIST (16); 13.1% mRECIST vs 7.8% RECIST 
1.1 (17). This finding has important implications, when combined with the observation 
that mRECIST response can reliably identify a subgroup of patients with a 
significantly better prognosis than those without response. Our results suggest that 
mRECIST may offer a suitable alternative to RECIST in Phase II clinical trials, in 
which detection of an efficacy signal is paramount. We also demonstrate that patients 
with PD measured by RECIST or mRECIST have a poor outcome, with a median 
survival of 4.3 months by either criteria. This observation suggests that treatment 
beyond radiological progression is not warranted and that patients should be actively 
monitored for radiological progression rather than waiting for symptomatic 
progression.  
The limitation of the relatively small dataset used in this analysis should be 
taken into account when interpreting these findings and considering their clinical 
utility. Nonetheless, our analyses have a number of strengths. First, analyses were 
based on prospectively collected data from two well-designed trials complying with 
the European Association for the Study of the Liver recommendations for the conduct 
of trials in patients with HCC (20). Second, all radiological assessments of response 
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were performed by a central imaging unit, improving the consistency of response 
assessment. Third, analysis showed that mRECIST response remains an 
independent surrogate for survival when other known prognostic factors are 
considered. However, it should be noted that AFP levels, of known independent 
prognostic significance in HCC, were not available from the dataset for inclusion in 
our analysis. Finally, it should be considered that the RECIST criteria used in these 
trials (RECIST 1.0) are not the most up-to-date RECIST criteria, although differences 
between versions 1.0 and 1.1 are minor and are not expected to have affected the 
overall conclusions of this study. Additionally, other methods of response assessment 
have been proposed, such as the Response Evaluation Criteria in Cancer of the Liver 
(RECICL) (21) and the Choi criteria (22), although these methods have yet to be 
prospectively validated in HCC. Both methods are more complex than RECIST; 
RECICL requires bidimensional measurements of tumour size, whereas the Choi 
criteria requires evaluation of tumour density by selecting a region of interest and, as 
such, is less easy to standardise for routine use. 
In conclusion, our findings show that objective mRECIST response is an 
independent marker for OS and support its use as a valid endpoint for use in HCC 
clinical trials of systemic therapy in HCC. To our knowledge, this is the first 
prospective validation of mRECIST and provides robust evidence to support 
management guidelines.  
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Tables and figures 
Table 1. Patient baseline demographics and clinical characteristics (all randomised patients) 
Characteristic 
Study 1 
 (n=93) 
Study 2 
(n=95) 
Combined 
(n=188) 
Age, years Median (range) 66.0 (28–86) 59 (32–84) 63 (28–86) 
Male sex; n (%) 
 
74 (79.6) 83 (87.4) 157 (83.5) 
Race; n (%) 
Indian 3 (3.2) – 3 (1.6) 
Taiwanese or Chinese 1 (1.1) 64 (67.4) 65 (34.6) 
Korean – 31 (32.6) 31 (16.5) 
Black 1 (1.1) – 1 (0.5) 
Caucasian 81 (87.1) – 81 (43.1) 
Missing 7 (7.5) – 7 (3.7) 
Time since diagnosis, months; median (range) 2.53 (0–101.4) 7.13 (0.1–131.3) 4.6 (0–131.3) 
ECOG PS; n (%) 
0 50 (53.8) 53 (55.8) 103 (54.8) 
1 38 (40.9) 41 (43.2) 79 (42.0) 
2 5 (5.4) 1 (1.1) 6 (3.2) 
Child–Pugh score; n (%) 
5 65 (69.9) 62 (65.3) 127 (67.6) 
6 27 (29.0) 32 (33.7) 59 (31.4) 
7a 1 (1.1) 1 (1.1) 2 (1.1) 
BCLC stage; n (%) 
0 1 (1.1) – 1 (0.5) 
A 1 (1.1) 2 (2.1) 3 (1.6) 
B 22 (23.7) 10 (10.5) 32 (17.0) 
C 68 (73.1) 83 (87.4) 151 (80.3) 
D 1 (1.1) – 1 (0.5) 
MVI; n (%) 
 
31 (33.3) 40 (42.1) 71 (37.8) 
EHS; n (%) 
 
61 (65.6) 65 (68.4) 126 (67.0) 
Location of EHS; n (%) 
Bone 11 (11.8) 9 (9.5) 20 (10.6) 
Lung 22 (23.7) 35 (36.8) 57 (30.3) 
Lymph 35 (37.6) 33 (34.7) 68 (36.2) 
Other 18 (19.4) 25 (26.3) 43 (22.9) 
Aetiology of 
parenchymal liver 
disease; n (%) 
Alcohol related 13 (14.0) 4 (4.2) 17 (9.0) 
HBV related 11 (11.8) 60 (63.2) 71 (37.8) 
HCV related 21 (22.6) 15 (15.8) 36 (19.1) 
HBV + HCV related 0 3 (3.2) 3 (1.6) 
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Unknown 31 (33.3) 11 (11.6) 42 (22.3) 
Other 17 (18.3) 2 (2.1) 19 (10.1) 
Parenchymal liver 
disease; n (%) 
Chronic hepatitis 13 (14.0) 26 (27.4) 39 (20.7) 
Steatofibrosis 5 (5.4) 0 5 (2.7) 
Cirrhosis 49 (52.7) 61 (64.2) 110 (58.5) 
No evidence 16 (17.2) 6 (6.3) 22 (11.7) 
Unknown 9 (9.7) 1 (1.1) 10 (5.3) 
Other 1 (1.1) 1 (1.1) 2 (1.1) 
Type of local therapy; n 
(%) 
Complete surgical 
resection 
12 (12.9) 9 (9.5) 21 (11.2) 
RFA 2 (2.2) 4 (4.2) 6 (3.2) 
TACE 29 (31.2) 48 (50.5) 77 (41.0) 
RT 1 (1.1) 2 (2.1) 3 (1.6) 
Other 6 (6.5) 11 (11.6) 17 (9.0) 
Stratification group; n 
(%) 
I: EHS and/or MVI 
present 
72 (77.4) 82 (86.3) 154 (81.9) 
II: EHS and MVI both 
absent 
21 (22.6) 13 (13.7) 34 (18.1) 
AFP group at baseline; n 
(%) 
≤20 μg/L 12 (12.9) 26 (27.4) 38 (20.2) 
>20 μg/L  18 (19.4) 69 (72.6) 87 (46.3) 
Missing 63 (67.7) 0 63 (33.5) 
ECOG PS, Eastern Cooperative Oncology Group performance status; BCLC, Barcelona Clinic Liver Cancer; MVI, 
macrovascular invasion; EHS, extrahepatic spread; HBV, hepatitis B virus; HCV, hepatitis C virus; RFA, 
radiofrequency ablation; TACE, transarterial chemoembolisation; RT, radiotherapy; AFP, alpha-fetoprotein. 
aPatients with a Child–Pugh score of 7 were protocol violations. 
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Table 2. Best overall response according to RECIST and mRECIST 
Best response, n (%) RECIST (n=180) mRECIST (n=180) 
Objective response  8 (4.4) 28 (15.6) 
Complete response  2 (1.1) 2 (1.1) 
Partial response  6 (3.3) 26 (14.4) 
Stable disease  141 (78.3) 123 (68.3) 
Progressive disease  31 (17.2) 29 (16.1) 
RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST. 
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Table 3. Concordance and discordance between RECIST and mRECIST response 
 Type of response (N=180) 
 
Objective 
response  
Complete 
response  
Partial 
response  
Stable 
disease  
Progressive 
disease  
Concordance 
between RECIST 
and mRECIST 
response, n (%) 
7 (3.9) 2 (1.1) 5 (2.8) 
120 
(66.7) 
29 (16.1) 
Concordance 
between RECIST 
non-response and 
mRECIST non-
response, n (%) 
151 (83.9) 178 (98.9) 153 (85.0) 36 (20.0) 149 (82.8) 
Discordance; 
RECIST 
response/mRECIST 
non-response, n (%) 
1 (0.6) 0 (0.0) 1 (0.6) 21 (11.7) 2 (1.1) 
Discordance; 
RECIST non-
response/mRECIST 
response, n (%) 
21 (11.7) 0 (0.0) 21 (11.7) 3 (1.7) 0 (0.0) 
RECIST, Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST. 
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Fig. 1. Waterfall plots showing best percentage change from baseline in sum of target lesion 
dimensions. (A) According to RECIST (n=170) criteria; (B) according to mRECIST (n=166) 
criteria. The total number of patients is less than the number of evaluable patients, as some 
patients had no evaluable target lesions according to central independent review. PD, 
disease progression; PR, partial response; RECIST, Response Evaluation Criteria in Solid 
Tumors; mRECIST, modified RECIST. 
(A) 
 
(B) 
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Fig. 2. Probability of overall survival in all patients and by RECIST/mRECIST response. (A) 
All patients; (B) By RECIST response; (C) By mRECIST response. Patients who had not died 
or who were lost to follow-up were censored on the last date on which they were known to 
have been alive. Shaded areas represent the 95% confidence limits. Hazard ratios represent 
patients with response compared to patients without response (yes vs no). RECIST, 
Response Evaluation Criteria in Solid Tumors; mRECIST, modified RECIST; OS, overall 
survival; CI, confidence interval; n.c., not calculable; HR, hazard ratio.  
(A) 
 
(B) 
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(C) 
 
 
 
Fig. 3. Hazard ratios for overall survival from multivariate analyses. RECIST, Response 
Evaluation Criteria in Solid Tumors; modified RECIST; CI, confidence interval. 
 
  
 
